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Abstract
Introduction: Tumor cell migration and invasion are critical initiation steps in the process of breast cancer
metastasis, the primary cause of breast cancer morbidity and death. Here we investigated the role of p21Cip1
(p21), a member of the core cell cycle machinery, in transforming growth factor-beta (TGFb)-mediated breast
cancer cell migration and invasion.
Methods: A mammary fat pad xenograft mouse model was used to assess the mammary tumor growth and local
invasion. The triple negative human breast cancer cell lines MDA-MB231 and its sub-progenies SCP2 and SCP25,
SUM159PT, SUM149PT, SUM229PE and SUM1315MO2 were treated with 5 ng/ml TGFb and the protein expression
levels were measured by Western blot. Cell migration and invasion were examined using the scratch/wound healing
and Transwell assay. TGFb transcriptional activity was measured by a TGFb/Smad reporter construct (CAGA12-luc) using
luciferase assay. q-PCR was used for assessing TGFb downstream target genes. The interactions among p21, p/CAF and
Smad3 were performed by co-immunoprecipitation. In addition, Smad3 on DNA binding ability was measured by DNA
immunoprecipitation using biotinylated Smad binding element DNA probes. Finally, the association among active
TGFb/Smad signaling, p21 and p/CAF with lymph node metastasis was examined by immunohistochemistry in tissue
microarray containing 50 invasive ductal breast tumors, 25 of which are lymph node positive.
Results: We found p21 expression to correlate with poor overall and distant metastasis free survival in breast
cancer patients. Furthermore, using xenograft animal models and in vitro studies, we found p21 to be essential for
tumor cell invasion. The invasive effects of p21 were found to correlate with Smad3, and p/CAF interaction
downstream of TGFb. p21 and p/CAF regulates TGFb-mediated transcription of pro-metastatic genes by controlling
Smad3 acetylation, DNA binding and transcriptional activity. In addition, we found that active TGFb/Smad signaling
correlates with high p21 and p/CAF expression levels and lymph node involvement using tissue microarrays from
breast cancer patients.
Conclusions: Together these results highlight an important role for p21 and p/CAF in promoting breast cancer cell
migration and invasion at the transcriptional level and may open new avenues for breast cancer therapy.
Introduction
p21 was originally identified as a cell cycle regulator
through inhibition of different cyclin/cyclin-dependent
kinase complexes [1]. p21 is a member of the Cip/Kip
family of cell cycle inhibitors, which also includes
p27Kip1 and p57Kip2 [2-4]. In addition to its role in cell
cycle control, p21 is involved in the regulation of cellular
senescence, gene transcription, apoptosis and actin cytos-
keleton [5-7]. The role of p21 in breast cancer develop-
ment and progression has not been fully investigated.
While p21 is involved in cell cycle control and is a down-
stream target of the tumor suppressor p53, it does
not fulfill the classic definition of a tumor suppressor.
Germline or somatic mutations in the p21 gene are not
common in human cancers [8]. Furthermore, in vivo stu-
dies using p21 knockout mice showed that, while loss of
p21 expression efficiently blocked the ability of the cells
to undergo G1 arrest following DNA damage, these
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animals developed normally [9]. Intriguingly, p21 is often
overexpressed in aggressive tumors, including carcino-
mas of the pancreas, breast, prostate, ovary and cervix
[10-13]. Together these observations suggest that the role
played by p21 in cancer is more complex than initially
thought and that, in addition to its well-known cell cycle
regulatory effect, it may have uncharacterized roles in
promoting carcinogenesis.
Tumor cell migration and invasion are critical steps in
the metastatic process and are regulated by numerous
tumor-secreted factors which modify the tumor microen-
vironment by acting on stromal recruitment and extracel-
lular matrix (ECM) degradation, resulting in tumor cell
migration and invasion [14]. Among these tumor-secreted
factors, TGFb has been shown to play a pivotal role in
promoting tumor metastasis [15]. The TGFb family regu-
lates asymmetric cell division and cell fate determination
during embryogenesis and exerts profound effects on
reproductive functions, immune responses, cell growth,
bone formation, tissue remodeling and repair throughout
adult life [16]. The effects of TGFb in breast cancer are
complex. TGFb is thought to play a dual role in breast
cancer progression, acting as a tumor suppressor in nor-
mal and early carcinoma, and as a pro-metastatic factor in
aggressive carcinoma [17]. The growth inhibitory effects of
TGFb are known to be mediated through transcriptional
repression of the c-myc gene [18] and induction of the cell
cycle inhibitors p15Ink4b (p15) and p21, leading to G1
arrest [19,20]. During tumor progression, however, the
loss of TGFb growth-inhibitory effects is frequently due to
defects in c-myc and p15 regulation by TGFb [18]. Mean-
while, other TGFb responses prevail, unrelated to growth
inhibition and favoring tumor progression and metastasis
[21-25]. Indeed, TGFb induces degradation of the ECM,
inhibits cell adhesion and stimulates cell migration and
invasion, thereby promoting tumor metastasis [21-23,25].
Moreover, during cancer progression, tumor cells secrete
increasing quantities of TGFb, which in turn alter the
stroma environment, leading to stimulation of tumor
angiogenesis and causing local and systemic immunosup-
pression, thus further contributing to tumor progression
and metastasis [21-23,25]. Together these studies highlight
an important role for TGFb in advanced breast cancer.
However, the function for p21 downstream of TGFb has
not been described in breast cancer.
In this study, we found that high p21 expression corre-
lates with poor survival in breast cancer patients. The
expression of p21 is required to promote tumor cell
migration and invasion in vitro and local invasion in vivo.
Furthermore, p21 expression is tightly regulated by
TGFb/Smad3 signaling in a panel of human basal-like tri-
ple negative breast cancer cell lines. We found p21 to
physically interact with Smad3 and the histone acetyl-
transferase p/CAF in response to TGFb and identified
p21 and p/CAF as key regulators of TGFb-mediated
breast cancer cell migration and invasion. We also
showed that p21 and p/CAF regulate TGFb transcrip-
tional activity on multiple tumor-promoting target genes
by controlling Smad3 acetylation and Smad3 occupancy
on its DNA binding elements. Immunohistochemical
analysis of tissue arrays from breast cancer patients
revealed a significant correlation between active TGFb/
Smad3 signaling and high expression levels of both p21
and p/CAF in lymph node-positive invasive ductal carci-
nomas. Together, our findings identified p21 and p/CAF
as critical regulators of cell migration and invasion down-
stream of TGFb/Smad3 pathway in advanced breast
cancer.
Methods
Cell culture and transfection
Human breast carcinoma MDA-MB231, SCP2 and SCP25
cells (provided by Dr. Joan Massagué) and HEK293 cells
were grown in DMEM supplemented with 10% fetal
bovine serum (FBS) and 2 mM L-glutamine at 37°C in 5%
CO2. SUM149PT, SUM159PT and SUM229PE (provided
by Dr. Stephen P Ethier) were grown in F-12 HAM’S
nutrient mixture (HyClone Laboratories, Inc. Logan, Utah,
USA) supplemented with 5% FBS, 5 µg/ml insulin (Sigma-
Aldrich, St. Louis, MO, USA), 1 µg/ml hydrocortisone
(Sigma) at 37°C in 5% CO2. SUM1315MO2 were grown in
F-12 HAM’S nutrient mixture (HyClone) supplemented
with 5% FBS, 5 µg/ml insulin (Sigma), 10 ng/ml epidermal
growth factor (EGF) (Sigma) at 37°C in 5% CO2.
Cells were transfected with different p21, p/CAF, Smad2
and Smad3 siRNAs (Sigma), 6× myc- Smad2, myc-Smad3,
p/CAF (Addgene plasmid 8941) [26] and Flag-tagged
human p21 cDNAs (Addgene plasmid 16240) [27] using
Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA,
USA ), according to the manufacturer’s protocol. MDA
and SCPs cells were serum-starved for 24 hrs and stimu-
lated or not with 5 ng/ml TGFb1 (PeproTech, Rocky Hill,
NJ, USA) in DMEM supplemented with 2 mM L-gluta-
mine. For stable cell line generation, SCP2 cells were
transfected with p21 shRNA (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and pools of stable cells were
selected with 10 ng/ml puromycin (Invitrogen).
SUM159PT cells were serum-starved for 24 hrs in the
absence of insulin and hydrocortisone before TGFb1
stimulation.
Western blot analysis and immunoprecipitation
Cells were lysed in cold extraction buffer (10 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 30 mM sodium
pyrophosphate, 50 mM sodium fluoride, 1 mM sodium
orthovanadate, 1% Triton X-100) containing protease inhi-
bitors (1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leu-
peptin hydrochloride, 10 µg/ml aprotinin and 10 µg/ml
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pepstatin A). The lysates were then centrifuged at 14,000
rpm for 15 minutes at 4°C. Protein content was measured
using BCA protein assay kit (Thermo Scientific, Rockford,
IL, USA). Equal protein was analyzed by Western blot
using mouse anti-p21 (F5), mouse anti-c-myc, mouse anti-
p15, rabbit anti-Smad2/3 (1:1,000 dilution, Santa Cruz
Biotechnology), phospho-cofilin and cofilin antibodies
(1:1,000 dilution, Millipore, Billerica, MA, USA), and fol-
lowed by secondary antibodies goat anti-mouse or rabbit.
Immunoprecipitations were performed overnight at 4°C
using antibodies against p300/CBP (Santa Cruz Biotech-
nology), p/CAF (Abcam®, Cambridge, MA, USA) and p21.
Protein G-Sepharose (GE Healthcare Bio-Sciences, Piscat-
away, NJ, USA) was added for 1 hr at 4°C, and washed
four times with cold lysis buffer. The immunocomplexes
were boiled with 2× sodium dodecyl sulfate (SDS)
Laemmli sample buffer for five minutes and subjected to
immunoblotting.
Histone proteins extraction
Total histone proteins were extracted as previously
described [28]. Briefly, 80% confluent of SCP2 cells from a
100-mm tissue culture plate were serum-starved for
24 hrs and stimulated with or without 5 ng/ml TGFb or
1 µM trichostatin A (TSA). SCP2 cells were harvested and
resuspended in cold hypotonic lysis buffer containing
10 mM Tris-HCl, pH 8.0, 1 mM KCl, 1.5 mM MgCl2,
1 mM DTT, protease inhibitors, 1 µM TSA and 10 mM
sodium butyrate. Cell lysates were rotated at 4°C for
30 minutes and then centrifuged at 10,000 g, 4°C, for
10 minutes. The supernatants were discarded and nuclei
pellets were resuspended in 400 µl of 0.4 N H2SO4 and
incubated overnight on a rotator at 4°C. Samples were
centrifuged at 16,000 g for 10 minutes and supernatants
containing histones were transferred into a fresh tube. A
total of 132 µl trichloroacetic acid was added drop by drop
to the histone solution, inverted several times and then
incubated on ice for 30 minutes. The histone precipitates
were centrifuged at 16,000 g for 10 minutes and pellets
were washed twice with ice-cold acetone and the histone
pellets were air dried for 20 minutes. Total histone pro-
teins were subjected to Western blot analysis using an
acetylated lysine antibody (Millipore).
DNA affinity precipitation assay
SCP2 cells transiently transfected with the indicated siR-
NAs were stimulated with TGFb for 30 minutes. Cell
lysate were extracted in cold lysis buffer containing
10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% Nonidet P-40, 30 mM sodium pyrophosphate, 1 mM
sodium orthovanadate and protease inhibitors as
described above. A total of 5 µg Poly (dI-dC) competitor
(Sigma) was incubated with 1 mg of total cell lysate for
30 minutes at 4°C. A total of 500 pmol of double-
stranded oligonucleotides (IDT) was added and incu-
bated with cell lysates for two hours at 4°C. Streptavi-
din-agarose beads (65 µl; Sigma) were added, incubated
overnight at 4°C and then washed three times with cold
lysis buffer. The streptavidin-agarose beads containing
biotinylated oligonucleotides and protein complex were
boiled with 2× SDS Laemmli sample buffer for five min-
utes and subjected to immunoblotting. The sequences
of biotin labeled double-strand oligonucleotides (IDT)
were previously described [29]. For Smad binding ele-
ment oligonucleotide (4× SBE), Sense: biotin-5’-CAGA-
CAGTCAGACAGTCAGACAGTCAGACAGT-3’, anti-
sense: 5’-ACTGTCTGACTGTCTGACTGTCTGACT
GTCTG-3’. For control oligonucleotide, sense: biotin-5’-
GCCCAGGCGCACCTGCTCCGATATCAATATCC
GGC-3’, anti-sense, 5’- GCCGGATATTGATATCG-
GAGCAGGTGCGCCTGGGC-3’.
Luciferase assays
SCP2 cells were transiently co-transfected with 50 nM
Scr siRNA, 50 nM p21 siRNA or 0.5 µg flag-tagged p21
cDNA in combination with 0.3 µg SBE reporter construct
(CAGA12-luc) and 0.1 µg pCMV-b-gal. Transfected cells
were then stimulated with or without 5 ng/ml TGFb for
16 hrs. Luciferase activity of CAGA12-luc was measured
(EG & G Berthold luminometer, Berthold Technologies,
Bad Wildbad, Baden-Württemberg, Germany) and nor-
malized to b-galactosidase activity.
Real-Time PCR
Total RNA was extracted using TRIzol reagents (Invitro-
gen). Reverse transcription of total RNA using random
primers was carried out using M-MLV reverse transcrip-
tase (Invitrogen) as per the manufacturer’s instructions.
Real-time PCRs were carried out using SsoFast™Eva-
Green® Supermix (Bio-Rad, Hercules, CA, USA) in a
Rotor Gene 6000 PCR detection system (MBI Lab Equip-
ment, Montreal Biotech Inc. Kirkland, PQ, Canada). PCR
conditions were as follows: 95°C for 30 s, 40 cycles (95°C
for 5 s and 60°C for 20 s). The primer sequences were as
follows: IL8 forward primer, GCAGAGGCCACCTG-
GATTGTGC; reverse primer, TGGCATGTTGCAGGCT
CCTCAGAA; IL6 forward primer, CTCCCCTCCAG-
GAGCCCAGC; reverse primer, GCAGGGAAGGCAG-
CAGGCAA; PLAU forward primer, GCCCTGGTTTGC
GGCCATCT; reverse primer, CGCACACCTGCCCT
CCTTGG; MMP9 forward primer, TGGACACGCAC-
GACGTCTTCC; reverse primer, TAGGTCACGTAGCC-
CACTTGGTCC; PTGS2 forward primer, AGCTTTCACC
AACGGGCTGGG; reverse primer, AAGACCTCCTG
CCCCACAGCAA; TGFBI forward primer, CGGCTGC
TGCTGAAAGCCGACCA; reverse primer, GGTCGG
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GGCCAAAAGCGTGT; p21 forward primer, TGTCCGC
GAGGATGCGTGTTC; reverse primer, GCAGCCCGC-
CATTAGCGCAT; GAPDH forward primer, GCCTCAA-
GATCATCAGCAATGCCT; reverse primer, TGTGGTC
ATGAGTCCTTCCACGAT.
Thiazolyl blue tetrazolium bromide (MTT) assay
A total of 100 µl of cell suspension (1× 105 cells/ml in
DMEM supplemented with 1% FBS) was stimulated or
not in the presence or absence of 5 ng/ml TGFb and
cultured in 96-well plates for two days. After two days,
25 µl 5 mg/ml MTT solution (Sigma) was added to
each well and incubated for two hours. A total of 200 µl
of dimethyl sulfoxide (DMSO) was added to each well
and mixed well. The absorbance at 570 nm was mea-
sured on a plate reader.
Cell cycle analysis
SCP2 cells were stimulated with TGFb for 0, 2, 6 and
24 hrs. Cells were then fixed with 70% ethanol over-
night, treated with 20 µg/ml RNase (Sigma), and stained
with 0.5 mg/ml propidium iodide (Santa Cruz Biotech-
nology). DNA content was determined using a FACScan
flow cytometry analyzer.
Kinetic cell migration assay
Cells were transfected with different siRNAs and plated in
Essen ImageLock 96-well plates (Essen Bioscience, Ann
Arbor, Michigan, USA) at 50,000 cells per well. The use of
ImageLock 96-well plates ensures that images/videos of
the wound are automatically taken at the exact same loca-
tion by the IncuCyte™software (Essen Bioscience). Cells
were then serum-starved for six hours and confluent cell
layers were scratched using the Essen Wound maker to
generate approximately 800 µm width wounds. After
wounding, cells were washed two times with PBS and sti-
mulated in the presence or the absence of 5 ng/ml of
TGFb. ImageLock 96-well plates were then placed into
IncuCyte (Essen Bioscience) and imaged every hour for
24 hrs. The data were analyzed by three integrated metrics:
wound width, wound confluence or relative wound density
automatically measured by the IncuCyte software.
Matrigel invasion assay
For the Transwell assays, 30 µl of growth factor reduced
(GFR) Matrigel (BD Biosciences, diluted 1:3 in pre-chilled
H2O) was coated onto each insert of 24-Tranwell inva-
sion plate (8-µm pore size; BD Biosciences) and incu-
bated for two hours in the cell culture incubator. SCP2
or SUM159PT (6 × 104 cells/insert) were seeded on
Transwell Insert coated GFR-Matrigel and cells in the
upper chamber were stimulated or not with 5 ng/ml
TGFb for 24 hrs. For SCP2 cells, bottom chambers con-
tained 10% FBS in DMEM medium. For SUM159PT
cells, bottom chambers were added to F-12 HAM’S med-
ium with 5% FBS. After 24 hrs, cells from the upper
chamber were removed by cotton swab and cells invaded
through GFR-Matrigel were fixed with 3.7% formalde-
hyde for 10 minutes and then stained with 0.2% crystal
violet for 20 minutes. Images of the invading cells were
photographed using an inverted 4× or 10× microscope
and total cell numbers were counted and quantified by
Image J software (National Institute of Health, Bethesda,
Maryland, USA).
Immunofluorescence microscopy
Cells were grown on coverslips at 50% confluence, stimu-
lated or not with TGFb overnight. Cells were then fixed
with 3.7% formaldehyde for 10 minutes and permeabilized
in 0.1% Triton X-100 for 3 minutes, washed with PBS and
blocked for 1 hr in 2% BSA. Cells were then incubated
with anti-p21 antibody for one hour, washed with PBS and
incubated with the secondary antibody Alexa Fluor®568
goat anti-rabbit IgG (1:800 dilution; Invitrogen) for one
hour. Stained coverslips were mounted with SlowFade®
Gold antifade reagent with DAPI (Invitrogen). Confocal
analysis was performed using a Zeiss LSM 510 Meta Axio-
vert confocal microscope (Carl Zeiss, Oberkochen, Baden-
Württemberg, Germany) using 63× objective.
Immunohistochemistry, scoring and statistical analysis
Tissue sections (5 µm) from breast carcinoma microarray
slides (BCR961 and T088, Biomax) were deparaffinized
and rehydrated. The patient characteristics are in Table S1
(Additional file 1). The slides were then placed in 10 mM
citrate buffer (pH 6.0) and boiled at 95°C for 15 minutes.
The primary antibodies used for immunohistochemistry
staining were AE1/AE3 (Thermo Scientific), p21 (c-19,
Santa Cruz Biotechnology), p/CAF (ab12188, Abcam),
phospho-Smad3 (Cell Signaling). HRP Polymer & DAB
Plus Chromogen (Thermo Scientific) was used for detec-
tion of p21, p/CAF and phospho-Smad3. The slides were
then counter stained with hematoxylin (Vector Labora-
tories, Burlingame, CA, USA) and dehydrated and
mounted for microscopic examination. All images were
scanned by ScanScope digital scanners (Aperio, Vista, CA,
USA). All samples were reviewed and scored by a patholo-
gist. The staining for p21, p/CAF and phospho-Smad3 was
scored from 0 to 4 as follows: 0, no staining; 1, <25%
tumor cells stained weakly; 2, 25 to 50% tumor cells
stained moderately; 3, >50% tumor cells stained moder-
ately; 4, >50% tumor cells stained strongly.
Correlations between phospho-Smad3, p/CAF and p21
were examined by the Pearson correlation test using
SPSS 19 software (IBM, Armonk, NY, USA). Associations
between these protein expressions and lymph node status
were assessed by Fisher’s exact test. P-value (two-sided)
<0.05 was considered statistically significant.
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Mammary fat pad and intratibia injections of nude mice
Four- to six-week old female Balb/c nude mice were
obtained from Charles River (Charles River Laboratories
International, Wilmington, MA, USA) and used as a
model for primary mammary tumor formation and local
invasion. The animal study was approved by the ethics
committee and all the experimental animal protocols were
in accordance with the McGill University Animal Care.
Following the administration of an anesthetic cocktail of
ketamine (50 mg/kg), xylazine (5 mg/kg) and aceproma-
zine (1 mg/kg) injected intramuscularly into the mice, par-
ental and shRNA p21 SCP2 cells were inoculated at 5×
105 cells per mouse in 100 μl of saline (20% Matrigel) with
a 30-gauge needle into the mammary pad. The tumor size
was measured once a week using a caliper. Tumor volume
was determined according to the formula: tumor volume
= shorter diameter2 × longer diameter/2. Sets of mice
(eight per group) were sacrificed at eight weeks post-injec-
tion to examine invasiveness of the primary tumor. At the
end of these studies, mammary tumors with surrounding
fat pad and tissues were fixed in 10% neutral-buffered for-
malin for one day. Sections of mammary tumor were
embedded in Tissue-Tek O.C.T. (VWR International,
Radnor, PA, USA) compound and 9 µm thick sections
were stained with hematoxylin and eosin. Images of the
tumors were photographed by light microscope using 10×
and 20× objectives.
For intratibia injections, parental and shRNA p21 SCP2
cells (2.0× 106) were injected intramuscularly into the left
tibia of two group mice (eight per group). The mice were
monitored weekly for tumor burden. Digital radiography
of the hind limbs of all animals was used to monitor the
development of skeletal lesions at four, six and eight
weeks post-injection in a MX-20 cabinet X-ray system
(Faxitron Bioptics, Tucson, Arizona, USA). On Week 8,
radiographs of anesthetized mice were taken and the
osteolytic lesion area was analyzed as previously described
[30]. The score of lesion area was measured as 0, no
lesions; 1, minor lesions; 2, small lesions; 3, significant
lesions with minor break of margins (1% to 10% of bone
surface damaged); 4, significant lesions with major break
in peripheral lesions (>10% of bone surface damaged).
Statistical analyses
Student’s t-test was used and differences between
groups were considered significant at *P < 0.05.
Results
p21 expression correlates with poor survival in breast
cancer patients
Previous studies have suggested that higher expression
of cytoplasmic p21 correlated with poor prognosis in
breast carcinomas [31-33]. To further explore the corre-
lation of p21 gene expression level with clinical outcome
in breast cancer patients, we utilized a recently pub-
lished gene profiling database of breast cancer patients
to assess p21 gene expression in overall survival (OS)
and distant metastasis-free survival (DMFS) outcomes
[34]. We analyzed the prognostic value according to the
median, upper and lower quartile expression levels of
p21 in the 20-year follow-up for OS (353 patients) and
DMFS (761 patients). As shown in Figure 1A-C (left
panels), elevated p21 expression significantly correlated
with poor OS in both median (Hazard Ratio (HR), 1.7;
1.1 to 2.6; P = 0.012) and upper quartile (HR, 2.1; 1.3 to
3.2; P = 0.0016), but not in the lower quartile (HR, 1.17;
0.77 to 1.78; P = 0.47). Furthermore, higher p21 levels
showed a similar pattern (HR, 1.3; 0.97 to 1.74; P =
0.075) in DMFS (Figure 1A-C, right panels). After 20
years follow-up, patients who are free of distant metas-
tasis showed reduced expression of the p21 gene and a
better survival rate. Although the prediction did not
show statistically significant results in the median
expression, the P-value of the p21 upper quartile (HR,
1.5; 1.1 to 2.1; P = 0.0099) did reach statistical signifi-
cance (Figure 1B, right panel). We also analyzed the
relationship of p21 expression and clinical outcomes in
both estrogen receptor positive (ER+) and negative (ER-
) breast cancer patients. p21 expression is highest in
patients with poor prognosis regardless of ER status
(Additional file 2, Figure S1). Even though one cannot
rule out that elevated p21 levels could also be found in
the stroma rather than the tumor cells themselves, these
data demonstrate that high p21 expression correlates
with poor clinical outcomes and suggest that elevated
p21 expression may play a role in promoting tumor
progression.
Silencing p21 prevents breast tumor local invasion in vivo
and cancer cell migration and invasion in vitro
To investigate the contribution of p21 to tumor formation
and progression in breast cancer, we used a bone-meta-
static cell line SCP2, a sub-progeny of the human triple
negative breast cancer MDA-MB231 (hereafter referred to
as MDA) cells [35]. We first assessed the effect of suppres-
sing p21 on tumor growth using a mammary fat pad xeno-
graft mouse model. A specific p21 shRNA was stably
transfected to generate a pool of p21-deficient SCP2 cells.
Knockdown of p21 using shRNA efficiently reduced p21
protein expression, as compared to parental SCP2 cells
(Figure 2A). Parental and shRNA p21 SCP2 cells were
orthotopically injected into the mammary fat pad of
female Balb/c nude mice (eight mice per group). Tumor
growth was monitored weekly. There was no difference in
the rate of primary tumor formation or tumor size
between animals injected with parental or p21-deficient
cells (Figure 2B), suggesting p21 is not likely involved in
tumor formation. Next, we evaluated the effect of p21
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Figure 1 High p21 expression correlates with poor survival in breast cancer patients. A-C, The relationship of higher p21 expression and
breast cancer outcome was assessed by Kaplan-Meier survival analysis. The survival rates were analyzed using three different and separate splits
of the patients, based on p21 expression levels (A, median; B, upper quartile; C, lower quartile). For each split, the patients were then divided
into high and low groups with respect to p21 expression. Overall survival (left panels) and distant metastasis-free survival (right panels) correlate
with p21 gene expression. Number of breast cancer patients at risk with higher expression (red) and lower expression (black) of p21 at the
indicated time points.
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Figure 2 Silencing p21 prevents breast tumor local invasion in vivo and cancer cell migration and invasion. A, Total lysates from
parental and shRNA p21 SCP2 cells were analyzed by immunoblotting for the protein levels of p21 and b-tubulin. B, Parental and shRNA p21
SCP2 cells were injected into the mammary glands of four- to six-week-old female Balb/c nude mice. The size of mammary tumor was
measured from two sets of mice (eight per group; error bars indicate SEM). C, Representative photographs show hematoxylin and eosin staining
of the mammary gland (tumor and fat pad) of 12- to 15-month-old mice. D and E, Transwell cell migration (left panel) and GFR-Matrigel
invasion assay (right panel) of parental and shRNA p21 SCP2 cells were performed. Graphs show total migrated and invaded cell number
counted by Image J (error bars indicate SEM; n = 3 independent experiments). Student’s unpaired t-test was used to compare parental vs.
shRNA p21 SCP2 groups. Differences were considered significant at *P < 0.05.
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depletion on tumor invasiveness, a critical step for early
tumor progression. Intact tumors were taken with the
overlaying skin and surrounding deep tissues and analyzed
by a pathologist. Tumor invasiveness was assessed by
determining the extent of infiltration of cancer cells to the
surrounding tissue (stroma, fat pad, skin and muscle tis-
sue), as previously described [36]. As shown in Figure 2C
(left panels), tumors from the parental SCP2 group dis-
played no clear margin with the surrounding tissues and
were deeply invading into nearby structures. In contrast,
tumors derived from animals transplanted with p21-
depleted SCP2 cells formed a well-encapsulated tumor
mass that did not invade the surrounding tissues (Figure
2C, right panels), strongly suggesting that p21 plays an
important role in tumor invasion. This was confirmed
in vitro, as p21 gene silencing in SCP2 cells inhibited
both cell migration and invasion (Figure 2D and 2E,
respectively).
As shown in Figure S2A (Additional file 3), none of the
animals in which parental or p21-depleted SCP2 cells
(eight per group) were injected into the mammary fat
pad developed any bone lesions after two months, the
date at which mice had to be sacrificed due to the tumor
size. This timing may have been insufficient for tumor
cells to grow into visible distant lesions in the mouse
[37]. Thus, to investigate whether p21 is involved in the
later stage of breast cancer progression, we examined its
involvement in the development of bone osteolytic
lesions using an intratibia injection model of parental
and p21-deficient SCP2 cells in female Balb/c nude mice.
By by-passing the early steps of metastasis, this experi-
mental model allows for the assessment of tumor cell
metastasis and survival in the bone marrow [38]. As
shown in Figure S2B, C (Additional file 3), following
X-ray examination of the bones, both groups of mice
developed secondary tumors that caused severe osteolytic
bone lesions, suggesting that p21 does not affect the later
stages of bone metastasis. Collectively, these results indi-
cate that while p21 is required for breast cancer cells to
acquire an invasive phenotype, its effect is restricted to
the earlier stages of tumor metastasis, namely induction
of local cell invasion from the tumor to the surrounding
tissues.
TGFb induces p21 expression in migratory and invasive
human breast cancer cells
p21 expression is tightly controlled by multiple signaling
pathways [7]. Among these and of particular interest is
the TGFb/Smad signaling pathway [15,25,39]. Therefore,
we examined the effect of TGFb on the expression levels
of p21 in several basal-like triple negative human breast
cancer cell lines. These include the ductal adenocarci-
noma MDA and its sub-progenies (SCP2 and SCP25)
[40], an invasive ductal carcinoma SUM159PT (hereafter
referred to as SUM159) derived from a patient with ana-
plastic carcinoma, an inflammatory invasive ductal carci-
noma SUM149PT (SUM149), a pleural effusion derived
SUM229PE (SUM229) and tumor cells derived from
metastatic nodule of a patient with infiltrating ductal car-
cinoma SUM1315MO2 (SUM1315) [41]. As shown in
Figure 3A, B, with the exception of SUM1315, TGFb
strongly induced p21 mRNA and protein levels in these
cell lines. Interestingly, TGFb showed no regulatory
effect on the expression levels of other cell cycle regula-
tory genes, such as c-myc and p15 (Figure 3C), consistent
with a loss of the TGFb growth inhibitory responses in
these cells (Figure 3C). Although p21 is a cell cycle inhi-
bitor, the TGFb-induced increases in p21 protein levels
did not translate into growth inhibition by TGFb (Addi-
tional file 4, Figure S3A), nor did it lead to G1 arrest in
these breast cancer cells (Figure S3B). We next investi-
gated the mechanisms by which TGFb regulates p21 pro-
tein levels. As shown in Figure 3D, the TGFb type I
receptor (TbRI) inhibitor SB431542 blocked TGFb-
induced p21 protein expression, indicating that TGFb
regulation of p21 expression is mediated through the
TGFb receptor signaling cascade. Furthermore, we found
this effect to be Smad-dependent and Smad3-specific, as
TGFb induced both phosphorylation of Smad2 and
Smad3 (Additional file 4, Figure S3C), but was unable to
induce p21 protein levels in MDA cells depleted of
Smad3 but not of Smad2 (Figure 3E). Collectively, these
data indicate that TGFb potently induces p21 expression
in a Smad3-dependent manner without affecting cell
growth or cell cycle progression in invasive human basal-
type breast cancer cells.
p21 expression is required for TGFb-mediated cell
migration
TGFb is an important modulator of cell motility in breast
cancer [25,42]. Thus, we investigated whether p21 could
act downstream of TGFb to promote cell migration. We
first examined the effect of TGFb on cell migration
dynamics using the scratch/wound healing assay coupled
to quantitative time-lapsed imaging (Essen IncuCyte™).
Cell migration was measured by three integrated metrics:
wound width, wound confluence and relative wound den-
sity, using the IncuCyte software. As shown in Figure 4A,
B, TGFb potently induced cell migration in MDA, SCP2
and SUM149. As a negative control, we also used
SUM1315 in which TGFb did not regulate p21 expression.
As expected, there was no effect of TGFb on cell migra-
tion in SUM1315 cells (Additional file 5, Figure S4A, B).
To then investigate whether p21 is required for TGFb-
induced cell migration, we knocked down p21 expression
using two specific siRNAs in SCP2 cells and assessed the
effect of TGFb on cell migration dynamics by the
scratch/wound healing assay. As shown in Figure 4C,
Dai et al. Breast Cancer Research 2012, 14:R127
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TGFb induced p21 expression in both mock and
scrambled (Scr) siRNA transfected cells, while this effect
was blocked in cells transfected with either p21 siRNAs,
confirming the specificity and efficacy of our p21 siRNAs.
Importantly, we found that while TGFb potently induced
cell migration in mock and Scr siRNA transfected SCP2
cells, this effect was completely blocked in cells in which
p21 expression was depleted (Figure 4D, E). The effect of
p21 siRNAs on TGFb-induced cell migration was similar
to that observed when cells were transfected with a
siRNA against Smad3, used here as a positive control
(Figure 4D, E). We also confirmed that these effects on
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Figure 3 TGFb induces p21 expression in migratory and invasive human breast cancer cells. A, Real-time PCR was performed to measure
the mRNA level of p21 gene (error bars indicate SD; n = 3 independent experiments) for the indicated cell lines. B, Cells were treated with or
without 5 ng/ml TGFb for the indicated times. Total cell lysates were analyzed for p21 and b-tubulin protein levels by Western blotting. C, Total
cell lysates were analyzed for c-myc, p15 and b-tubulin protein levels by Western blotting. D, SCP25 cells were pretreated with 10 µM TGFb type
I receptor (TbRI) inhibitor (SB431542) or vehicle (DMSO) for 30 minutes and then stimulated with TGFb. Total cell lysates were analyzed for p21
and b-tubulin protein levels by Western blotting. E, MDA cells were transfected with 40 nM Scrambled (Scr), Smad2 or Smad3 siRNAs in
response to TGFb. Total cell lysates were analyzed for Smad2/3, p21 and b-tubulin protein levels by Western blotting.
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Figure 4 p21 expression is required for TGFb-mediated cell migration. A, Representative images of phase contrast and wound mask of
indicated cell lines stimulated with TGFb in scratch/wound healing assay. The initial wound mask (black) and wound closure (grey) were
measured using the Essen Instruments Scratch Wound Module. B, The time course of cell migration for the indicated cell lines was quantified
using the relative wound density metrics at two-hour time intervals (error bars indicate SEM; n = 3 independent experiments). C, SCP2 cells were
transfected with Scr or p21 siRNAs and then stimulated with or without TGFb for 24 hrs. Total cell lysates were analyzed for p21 and b-tubulin
by Western blotting. D, Representative images of phase contrast (top panels) and wound mask (bottom panels) of transfected SCP2 cells with
the indicated siRNAs in scratch/wound healing assay. E, The time course of transfected SCP2 cell migration was quantified using the relative
wound density metrics at two-hour time intervals (error bars indicate SEM; n = 3 independent experiments).
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cell migration were not secondary to changes in cell
growth, as silencing of p21 expression had no effect on
cell growth and proliferation (Figure S4C). These results
demonstrate that TGFb-mediated migration of human
breast cancer cells is dependent on TGFb-induced p21
expression.
p21 expression is required for TGFb-mediated cell
invasion
To examine the role of p21 in TGFb-induced tumor cell
invasion, SCP2 cells were transiently transfected with a Scr
siRNA, a p21 siRNA or a Smad3 siRNA. The invasive
potential of the cells was assessed using a GFR-Matrigel
Transwell assay. As shown in Figure 5A, B, in mock and
Scr siRNA transfected breast cancer cells, TGFb signifi-
cantly promoted cell invasion through the Matrigel and
this effect was completely blocked in the absence of p21.
Importantly, the inhibitory effect of the p21 siRNA on
TGFb-induced cell invasion was comparable to the effect
of the Smad3 siRNA. To demonstrate the specificity of the
p21 effect, we performed a rescue experiment. SCP2 cells
in which endogenous p21 expression was silenced
were transfected or not with a flag-tagged p21 cDNA
(Figure 5C). In this setup, overexpression of the flag-p21
overrode the siRNA effect and restored p21 protein level
(Figure 5C) as well as TGFb-induced cell invasion through
the GFR-Matrigel barrier (Figure 5D), indicating this effect
is specifically mediated through p21. To avoid the limita-
tion of the use of a single cell line, we also assessed the
pro-invasive effect of p21 in SUM159 cells. Overexpressing
or blocking p21 gene expression in these cells did not
alter their growth in response to TGFb (Additional file 6,
Figure S5). Importantly, as shown in Figure 5E, F, we found
SUM159 to be highly responsive to TGFb-induced cell
invasion. However, in the absence of p21 expression, the
TGFb pro-invasive effect was blocked, while overexpres-
sion of p21 potentiated this effect, similar to what was
observed in SCP2 cells. Our results demonstrate that
TGFb-mediated migration and invasion of human breast
cancer cells are dependent on TGFb-induced p21 expres-
sion. Interestingly, the p21 effects are not limited to TGFb
signaling as blocking p21 expression also affected serum
and EGF-induced cell invasion (Additional file 7, Figure
S6). These results suggest that p21 plays a broad regulatory
role in breast cancer cell invasion and may also explain the
strong phenotype observed in vivo, on local tumor cell
invasion, following p21 gene silencing (Figure 2C).
p21 interacts with Smad3 and modulates TGFb-induced
transcriptional activity and downstream genes involved in
cell invasion
It has been previously shown that cytoplasmic p21 regu-
lates actin cytoskeleton through binding and inhibiting
ROCK1, resulting in decreased phosphorylation of actin-
depolymerizing protein cofilin and increased cell migra-
tion in NIH3T3 fibroblasts and HeLa cells [43,44].
Therefore, we examined the phosphorylation and total
protein expression levels of cofilin in breast cancer cells
in response to TGFb. As shown in Figure S7A (Addi-
tional file 8), TGFb has no effect on the phosphorylation
of cofilin. As cytoplasmic p21 contributes to regulate
cofilin, we then examined the localization of p21 under
the stimulation of TGFb. Treatment with TGFb caused
accumulation of p21 in the nucleus in a time-dependent
manner (Figure S7B). This suggests that TGFb-induced
and p21-driven cell migration and invasion in human
breast cancer cells are not mediated through the ROCK/
LIMK/cofilin pathway. Besides its function as a cell
cycle regulator, p21 has also been shown to interact
with multiple transcription factors [7] to selectively inhi-
bit or induce expression of sets of genes involved in dis-
tinct biological functions, such as mitosis, DNA repair,
survival and ECM components [45]. Thus, we investi-
gated whether p21 could interact with the Smad pro-
teins to regulate the TGFb pro-invasive effects. Smad/
p21 interactions were analyzed by co-immunoprecipita-
tion studies in HEK293 and SCP2 cells co-transfected
with myc-Smad2, myc-Smad3 and flag-p21. As shown in
Figure 6A, while we could not detect any ligand-induced
association between Smad2 and p21, we found TGFb to
clearly induce complex formation between Smad3 and
p21 in the two cell lines. To assess the impact of the
p21/Smad3 interaction on TGFb signaling, we then
examined the effect of p21 on TGFb-induced Smad3
activity. As shown in Figure 6B, we found that knocking
down p21 did not affect TGFb-induced Smad3 phos-
phorylation. However, using a TGFb/Smad transcrip-
tional reporter construct (CAGA12-luc), we found that
p21 is required for TGFb-induced Smad transcriptional
activity. Indeed, as shown in Figure 6C, p21 gene silen-
cing abolished TGFb-induced luciferase activity of the
Smad reporter construct. Conversely, CAGA12-luc
activity was markedly potentiated in SCP2 cells overex-
pressing p21 in response to TGFb. These results indi-
cate that TGFb induces a complex formation between
p21 and Smad3 and that while p21 does not affect the
earlier stages of Smad3 activation (that is, phosphoryla-
tion), it is required for TGFb-mediated Smad transcrip-
tional activity.
We next performed gene profiling experiments in par-
ental and p21-deficient SCP2 cells, using transiently
transfected p21 siRNA as well as stably transfected p21
shRNA. Our arbitrary cutoff was set up at a minimum
of two-fold induction. This led us to identify multiple
p21-dependent TGFb target genes, among which were
selected those known to be associated with the tumor
metastasis process. This shortlist included five candidate
target genes: interleukin 6 (IL6), chemokine (IL8),
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Figure 5 p21 expression is required for TGFb-mediated cell invasion. A, SCP2 cells were transfected with the indicated siRNAs and cultured
in the presence or absence of TGFb. GFR-Matrigel coated Transwell invasion assay was performed and images of the invading cells were
photographed. B, Total cell number was counted by Image J and fold induction was quantified (error bars indicate SD; n = 3 independent
experiments). C, SCP2 cells were transfected with a Scr or p21 siRNA as well as a flag-tagged p21 cDNA in the presence or the absence of TGFb.
p21 protein levels were then analyzed by Western blotting. D, Cell invasion was assessed using the Transwell Invasion assay. The number of
invaded cells was counted by Image J (error bars indicate SD; n = 3 independent experiments). E, Cell invasion of transfected SUM159 was
assessed using the Transwell Invasion assay. F, Total cell number was counted by Image J and fold induction was quantified (error bars indicate
SD; n = 3 independent experiments).
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Figure 6 p21 interacts with Smad3 and modulates TGFb-induced transcriptional activity. A, HEK293 and SCP2 cells were co-transfected
with myc-Smad2, myc-Smad3 and flag-p21. Transfected cells were stimulated TGFb for 8 hrs. Cell lysates were immunoprecipitated with an anti-
flag antibody and analyzed by immunoblotting using Smad2/3 and p21 antibodies. B, Transfected MDA cells were immunoblotting by phospho-
Smad3 (p-Smad3), Smad2/3 and b-tubulin antibodies in response to TGFb for 30 minutes. C, SCP2 cells were co-transfected with either mock,
Scr siRNA, p21 siRNA or flag-tagged p21 construct (p21 cDNA) and SBE promoter construct (CAGA12-luc). Transfected cells were stimulated with
or without TGFb for 16 hrs. Luciferase activity of CAGA12-luc was measured and normalized to b-galactosidase (error bars indicate SEM; n = 3
independent experiments). D and E, SUM159 and SCP2 cells were treated with or without TGFb for the indicated times. The mRNA levels of
indicated genes were then analyzed by real-time PCR (error bars indicate SEM; n = 3 independent experiments).
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prostaglandin-endoperoxide synthase 2 (PTGS2), plasmi-
nogen activator (PLAU) and matrix metalloproteinase
(MMP9) [46]. To confirm that these genes were TGFb
downstream targets, SCP2 and SUM159 cells were sti-
mulated or not with TGFb and mRNA levels for these
target genes were analyzed by quantitative real-time
PCR (q-PCR). As shown in Figure 6D, E, TGFb signifi-
cantly increased the mRNA levels of IL6, IL8, PTGS2,
PLAU and MMP9 in a time-dependent manner in both
cell lines.
To then address the role of p21 in the transcriptional
regulation of these genes by TGFb, we examined the
effects of either silencing (using siRNA) or overexpressing
p21 cDNA in SUM159 cells. As shown in Figure 7A,
knocking down p21 gene expression blocked the TGFb
transcriptional regulation of IL6, IL8, PLAU, MMP9 and
PTGS2, indicating that p21 is required for TGFb to induce
expression of these target genes. The same results were
obtained in another breast cancer cell line (SCP2; data not
shown). On the other hand, p21 overexpression in these
cell lines potentiated the TGFb transcriptional effects on
these target genes. As a negative control and to ensure
specificity of our results, we also analyzed the effect of
silencing p21 on the TGFb-mediated increase in trans-
forming growth factor beta induced (TGFBI) mRNA.
TGFb regulated TGFBI mRNA independently of p21
(Figure 7B).
To address the contribution of these identified p21-
dependent TGFb target genes (IL6, IL8, PLAU, MMP9
and PTGS2) in regulating cell invasion, we silenced their
gene expression using specific siRNAs. As shown in
Figure 7C, D, inhibition of all five target genes impaired
TGFb-induced cell invasion, to a different extent. While
depletion of IL6, PLAU and MMP9 drastically antago-
nized the TGFb response, inhibition of PTGS2 and IL8
showed a moderate inhibitory effect. Moreover, examina-
tion of the siRNA effect on basal cell invasion indicated
that IL6 and PLAU did not affect basal invasion, suggest-
ing that they may be specifically required for the TGFb
pro-invasive response. On the other hand, inhibition of
MMP9, PTGS2 and IL8 clearly affected basal cell invasion
suggesting that these target genes have a broader effect
on cell invasion, not limited to the TGFb signaling path-
way. Together, these results indicate that even though all
five genes are important for TGFb signaling leading to
cell invasion, IL6, PLAU and MMP9 exert more predomi-
nant roles.
p21/p/CAF regulates TGFb transcriptional activity and
Smad3 DNA binding
p21 has been implicated in the control of gene transcrip-
tion by associating with various transcription factors [7],
but also regulates estrogen receptor-a-dependent gene
expression by activating p300-CREBBP-driven (CBP)
[47,48]. Gene transcription downstream of TGFb signal-
ing is also regulated by acetyltransferases, such as p300/
CBP and p300/CBP-associated factor (p/CAF), a member
of another HAT family, the so-called GCN5-related N-
acetyl transferases [49-52]. Thus, we examined whether
p21 could associate with either p300/CBP or p/CAF in
response to TGFb. Interestingly, we found that while
TGFb did not induce association between p21 and p300/
CBP, it strongly induced complex formation between p21
and p/CAF in both SCP2 and SUM159 breast cancer
cells (Figure 8A, left and right panels).
A previous report indicated that p/CAF directly binds
to Smad3 [50]. As we have shown that TGFb induces
complex formation between Smad3 and p21 (Figure 6A),
we investigated whether endogenous p/CAF is also
required for Smad3 association with p21. For this,
HEK293 cells were co-transfected with myc-Smad2, myc-
Smad3 and flag-p21 with or without p/CAF siRNA to
block expression of endogenous p/CAF. As shown in
Figure 8B, TGFb induced complex formation between
p21 and Smad3, independently of Smad2. Interestingly,
depletion of p/CAF completely prevented this interac-
tion, indicating that endogenous p/CAF is required for
Smad3 interaction with p21.
To investigate whether p/CAF is necessary for the regu-
lation of p21-dependent TGFb downstream target genes,
SUM159 cells were transiently transfected with flag-tagged
p21 in the presence or the absence of two different p/CAF
siRNAs. The gene expression of p/CAF (also known as K
(lysine) acetyltransferase 2B, KAT2B) was measured to
verify the efficiency of p/CAF knockdown by q-PCR
(Figure 8C). Overexpression of p21 potentiated induction
of IL6, IL8 and PTGS2 mRNA by TGFb. However, these
effects were significantly blocked when p/CAF gene
expression was silenced, indicating that p/CAF is required
for p21-dependent gene expression of the TGFb targets
(Figure 8D). The requirement of p/CAF downstream of
TGFb was further investigated using the Transwell Matri-
gel assay. As shown in Figure 8E, knocking down p/CAF
gene expression significantly impaired TGFb-induced cell
invasion. Efficiency of the siRNA was verified by Western
blotting (Figure 8F).
Because acetyltransferase p/CAF regulates gene tran-
scription by acetylating histones and transcription factors
[49], we then assessed whether TGFb could induce global
changes in histone acetylation in breast cancer cells. For
this, total histone proteins were extracted from SCP2 cells,
treated or not with TGFb and subjected to immunoblot-
ting using an acetylated lysine antibody. As shown in Fig-
ure S8 (Additional file 9), TGFb had no effect on global
histone acetylation while TSA, a histone deacetylase inhi-
bitor, showed a marked increase in the acetylation levels.
This suggested that the functional relevance of the p/CAF
recruitment to the p21/Smad complex may be more
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Figure 7 p21 regulates TGFb-induced downstream genes involved in cell invasion. A, SUM159 cells were transfected with Scr or p21 siRNA
as well as p21 cDNA. Cells were then treated with or without TGFb and the mRNA levels of indicated genes were analyzed by real-time PCR
(error bars indicate SEM; n = 3 independent experiments). B, SUM159 cells transfected with Scr siRNA and p21 siRNA were treated with TGFb for
the indicated times. The mRNA level of TGFBI gene was measured by real-time PCR (error bars indicate SEM; n = 3 independent experiments). C,
SCP2 cells were transfected with the indicated siRNAs. Cell invasion was assessed using the Transwell Invasion assay. D, Total cell number was
counted by Image J and number of invaded cells was quantified (error bars indicate SEM; n = 3 independent experiments).
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Figure 8 p21/p/CAF regulates TGFb transcriptional activity and Smad3 occupancy on SBE. A, SCP2 and SUM159 cells were treated with
TGFb. Cell lysates were analyzed by co-immunoprecipitation using specific antibodies, as indicated. B, HEK293 cells were co-transfected with
myc-Smad2, myc-Smad3 and flag-p21 with or without p/CAF siRNA. Transfected cells were stimulated with TGFb for eight hours. Cell lysates
were immunoprecipitated with an anti-flag antibody and analyzed by immunoblotting using Smad2/3 and flag antibodies. C and D, SUM159
cells were transfected with Scr or p/CAF siRNAs as well as a flag-tagged p21 cDNA, treated with or without TGFb. The mRNA levels of indicated
genes were analyzed by real-time PCR (error bars indicate SEM; n = 3 independent experiments). E, SCP2 cells transfected with Scr and p/CAF
siRNA were stimulated with or without TGFb. Cell invasion was quantified by relative TGFb fold induction (error bars indicate SEM; n = 3
independent experiments). F, Transfected SCP2 cells were subjected to immunoblotting p/CAF and b-tubulin. G, HEK293 cells were co-
transfected with myc-Smad3, myc-Smad2 and p/CAF. Immunoprecipitated Smad2/3 using an anti-myc antibody was subjected to Western
blotting. H, DNA precipitation (DNA IP) was performed using biotinylated control and 4× CAGA SBE oligonucleotides, following by streptavidin
precipitation. Western blotting of Smad3 and p/CAF is shown. I, SCP2 cells were transfected with p21 or p/CAF siRNAs. Samples were subjected
to DNA IP and immunoblotting of Smad3. J, Transfected SCP2 cells were stimulated with or without TGFb for 16 hrs. Luciferase activity of
CAGA12-luc was measured and normalized to b-galactosidase (error bars indicated SEM; n =3 independent experiments).
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directed towards acetylation of specific targets rather than
global histone modifications. To address this, we examined
whether p/CAF could acetylate p21 and/or the Smads.
Interestingly, we found that p/CAF is capable of interact-
ing with Smad2 and Smad3, leading to an increased acety-
lation of both Smad proteins (Figure 8G). Moreover, the
acetylation is specific to Smad2 and Smad3, as p21 did not
show any increased acetylation by p/CAF (data not
shown). Smad3 acetylation has been suggested to be
required for its DNA binding activity [51]. Thus, this led
us to investigate whether p/CAF could associate with
DNA-bound Smad3, by DNA immunoprecipitation (DNA
IP) using biotinylated control and biotinylated Smad bind-
ing element (4× CAGA) DNA probes. As shown in the
Figure 8H, we found TGFb to specifically induce binding
of both Smad3 and p/CAF to DNA. Furthermore, we
found that gene silencing of p/CAF and p21, using siR-
NAs, prevented Smad3 binding to the SBE (Figure 8I),
suggesting that both p21 and p/CAF are required for
Smad3 DNA binding and Smad3-mediated transcriptional
activity. Having shown that p21 is indeed required for
Smad3-mediated transcriptional activity (Figure 6C), we
then assessed the effect of knocking down p/CAF on
Smad3 transcriptional activity using the CAGA12-luc
reporter construct. As shown in Figure 8J, the results
clearly indicate that p/CAF is required for TGFb-induced
Smad3 transcriptional activity.
Collectively, these data indicate that p21 and p/CAF reg-
ulate TGFb transcriptional activity by controlling Smad3
occupancy on its DNA binding elements. TGFb induces a
complex formation between Smad3, p21 and p/CAF,
further leading to Smad3 acetylation by p/CAF. Further-
more, both p21 and p/CAF are required for Smad3 DNA
binding and Smad3-mediated transcriptional activity,
highlighting a novel mechanism by which the p21/p/CAF/
Smad3 complex contribute to the activation of TGFb tar-
get gene transcription.
High expression of p/CAF/p21/p-Smad3 is associated
with lymph node positivity
Lymph node involvement is an important prognostic
indicator in clinical breast cancer outcomes [53]. High
expression of TGFb1 is correlated with a high incidence
of lymph node metastasis [54]. To examine the associa-
tion among active TGFb/Smad signaling, p21 and p/
CAF with lymph node metastasis, we performed immu-
nohistochemistry to measure the expression levels of
serine 423/425 phosphorylated Smad3 (pSmad3), p21
and p/CAF in tissue microarray containing 50 invasive
ductal breast tumors, 25 of which are lymph node posi-
tive. The immunoreactivity for pSmad3, p21 and p/CAF
protein expression in tumor cells was graded and
described in Methods. We considered a score of 0 to 2
as a low phosphorylation/expression level and a score of
3 to 4 as a high phosphorylation/expression level. As
shown in Figure 9A, B, lymph node negative patients
showed low levels of pSmad3, p21 and p/CAF expres-
sions, whereas a significant enrichment of high pSmad3
(68%), p21 (68%) and p/CAF (80%) was observed in
patients with positive lymph nodes (P = 0.009, P =
0.004, and P = 0.001, respectively). To distinguish
between tumor cells and stroma, we used a cytokeratin
antibody (AE1/AE3), a cell marker specific to neoplastic
cells of epithelial origin. As shown in Figure S9 (Addi-
tional file 10), p21 is specifically expressed at a higher
level in breast tumor cells but not in stroma cells. We
also examined the relationships between pSmad3 levels
and p/CAF protein expression with p21 protein levels,
using the Pearson’s correlation test. As shown in Figure
9C, our results clearly indicate that high levels of phos-
phorylated Smad3 and p/CAF expression significantly
correlate with high p21 protein expression. Collectively,
these data indicate that active TGFb/Smad3 signaling is
associated with high p21 and p/CAF protein expression
levels and significantly correlates with lymph node
metastasis in breast cancer.
Discussion
While p21 was initially characterized as an important cell
cycle inhibitor, recent studies suggest that cytoplasmic
p21 has anti-apoptotic and actin cytoskeleton regulatory
functions [27,43,55]. The accumulation of cytoplasmic
p21 is associated with Ras and HER2/neu activated
tumorigenic transformation [32,44]. Moreover, overex-
pression of p21 is associated with poor prognosis of
many types of cancer. However, the function of p21 in
breast cancer has not been established. In our study, we
assessed p21 levels with clinical outcomes in breast can-
cer patients. High p21 expression correlates with poor
overall survival and distant metastasis free survival.
Furthermore, using an in vivo model of mammary fat pad
transplantation of metastatic human breast cancer cells
in mice, we showed that while silencing p21 gene expres-
sion did not affect the primary tumor formation, it
potently prevented primary tumor cells to invade into
surrounding tissues. Together, our results provide evi-
dence of a tumor-promoting role for p21 in primary
tumor local invasion.
Previous studies have indicated that during breast can-
cer progression, TGFb cytostatic responses are lost while
pro-migratory and pro-invasive effects are maintained
[56]. Here, we found that all invasive breast cancer cell
lines tested were resistant to growth inhibition by TGFb
and that while TGFb did not induce any change in p15
or c-myc expression levels, it strongly up-regulated p21
expression arguing that in advanced breast cancer p21
functions independently of cell cycle regulation. This is
in contrast to the effect observed in human immortalized
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Figure 9 High expression of p/CAF/p21/pSmad3 is associated with lymph node positivity. A, Representative immunohistochemistry
images of pSmad3, p21 and p/CAF in breast cancer tissue microarray samples. B, Overall pSmad3, p21 and p/CAF immunohistochemistry
staining intensity between lymph node negative (LN-) and positive (LN+) tissues. C, Percentage of case distribution according to
immunoreactivity of pSmad3, p21 and p/CAF in tumor cells, the score for negative (0), low (1 to 2) and high (3 to 4).
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the keratinocyte cell line HaCaT, where TGFb-mediated
p21 gene expression leads to cell cycle arrest [39]. Indeed,
we found that the induction of p21 in invasive breast
cancer cells is required for the pro-migratory and pro-
invasive effects of TGFb. In accordance with these
results, depletion of p21 did not modulate primary tumor
growth in vivo but strongly blocked tumor invasion capa-
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Figure 10 Model of pro-invasive function for the cell cycle regulator p21 in human breast cancer. The role of p21 as both a direct
transcriptional target of TGFb and a co-stimulatory factor of p/CAF/Smad3 in regulation of pro-invasive genes in triple negative breast cancer cells.
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a direct oncogenic role for p21 in breast cancer
progression.
We further report that the TGFb-mediated increase
in p21 expression is Smad-dependent and Smad3 spe-
cific. This is interesting in light of previous reports
indicating that overexpression of a dominant negative
form of Smad3 reduced the ability of cancer cells to
metastasize [57] and that Smad3, but not Smad2, pro-
motes breast cancer metastasis in mice [58]. Further-
more, while Smad2 mutations in cancer have been
described, no mutations in Smad3 or p21 have yet
been reported. Together these data suggest that in
breast cancer Smad3 pro-invasive functions are
mediated by p21 and that targeting p21 may prove
useful to improve the clinical course of metastatic
patients.
Tumor cell migration and invasion are critical initiation
steps in the process of breast cancer metastasis. It has
been suggested that cytoplasmic p21 regulates ROCK/
LIMK/cofilin pathway to promote cell migration; how-
ever, we found that TGFb had no effect on regulating
cofilin activity in breast cancer cells. In our studies, we
identified a novel role for p21 in the transcriptional regu-
lation of TGFb/Smad3 signaling through the interaction
of p21 and Smad3 in invasive breast cancer cells. The
interaction between p21 and Smad3 was p/CAF-depen-
dent, but whether this interaction is direct will require
further investigation. Furthermore, the effects of p21 on
cell migration and invasion are mediated through inter-
actions with Smad3 and p/CAF, which in turn modulate
Smad3 acetylation, DNA binding and transcriptional
activity, as well as gene transcription of several TGFb
pro-invasive downstream target genes. It will be interest-
ing to further investigate whether p21 is selective for the
pro-oncogenic activity of TGFb or whether it is also
required for the transcriptional regulation of other types
of TGFb responses and target genes. Taken together, our
results demonstrate that p21 is both a direct transcrip-
tional target of TGFb and a co-stimulatory factor of
Smad3 in regulation of pro-invasive genes in breast can-
cer cells (Figure 10).
Finally, we investigated the clinical relevance of TGFb-
mediated p21/p/CAF pathway in breast cancer. The
prognosis of breast carcinomas is related to various clini-
cal and pathological parameters. Axillary lymph node
metastasis is one of the most important prognostic para-
meters in the absence of distant metastasis. There is a
sharp difference in survival rate between patients with
positive and negative lymph nodes. In our studies, we
found a significant association of active TGFb/Smad3 sig-
naling, p21 and p/CAF expression with lymph node posi-
tivity, making them potential useful prognosis markers
for lymph node metastasis.
Conclusion
In this study, we described a pro-invasive function for the
cell cycle regulator p21 in human breast cancer. High
expression of p21 positively correlated with poor overall
and distant metastasis-free survival outcomes in breast
cancer patients. We identified p21 as a novel downstream
regulator of TGFb-mediated breast cancer cell migration
and invasion. We found p21 to interact with Smad3 and
the acetyltransferase p/CAF and to regulate the Smad
transcriptional activity, as well as gene transcription of sev-
eral TGFb-induced pro-metastatic genes. These results
highlight an important role for p21/p/CAF in TGFb-
induced breast cancer cell migration and invasion at the
transcriptional level.
Additional material
Additional file 1: Table S1: Patient characteristics from breast
carcinoma microarray tissue sections. The patient characteristics
including tumor grade, TNM and lymph node involvement are provided
for breast carcinoma microarray slides (BCR961 and T088, Biomax).
Additional file 2: Figure S1: The relationship between p21
expression and clinical outcomes in ER+ and ER- breast cancer
patients. A and B, The correlation of p21 expression with overall survival
and distant metastasis free survival in ER+ and ER- breast cancer patients
was assessed by Kaplan-Meier survival analysis. The patients were divided
into high or low groups based on the median of p21 expression.
Number of breast cancer patients at risk with higher expression (red) and
lower expression (black) of p21 at the indicated time points.
Additional file 3: Figure S2: Knocking down p21 does not affect
bone osteolytic lesions. Representative radiographs of skeletal lesions in
two groups of mice (parental and shRNA p21) were taken by X-ray using
Faxitron. A, parental and shRNA p21 SCP2 cells were injected in
orthotopic site (mammary gland). B and C, parental and shRNA p21 SCP2
cells were injected in tibia. The lesions are highlighted by arrows. The X-
ray scores of bone lesions at Week 8 are shown for the two groups of
animals. Data are reported as the mean ± SEM of eight animals in each
group and the X-ray scoring differences were tested by an independent
two-sample t-test. No statistically significant difference was observed
between the two groups (P = 0.81). P < 0.05 was considered to be
statistically significant.
Additional file 4: Figure S3: TGFb has no effect on cell growth or
cell cycle progression in basal-type triple negative breast cancer
cells. A, The indicated cell lines were stimulated with TGFb for 48 hrs
and subjected to MTT assay (error bars indicate SD; n = 3 independent
experiments). B, SCP2 cells were incubated with or without TGFb for the
indicated times and cell cycle distribution was determined by flow
cytometry. C, MDA cell lysates were analyzed for phospho-Smad2,
phospho-Smad3 and total Smad2/3 protein levels by Western blotting.
Additional file 5: Figure S4: Effect of TGFb on cell migration in
SUM1315. A, Representative images of phase contrast and wound mask
of SUM1315 cell line stimulated with TGFb in scratch/wound healing
assay. B, The time course of cell migration for SUM1315 was quantified
using the relative wound density metrics (error bars indicate SEM; n = 3
independent experiments). C, Cell viability (MTT) assay of transfected
SCP2 cells subjected to scratch/wound healing assay.
Additional file 6: Figure S5: Effect of p21 expression on cell
proliferation. SUM159 cells were transfected with a Scr siRNA, a p21
siRNA and a flag-tagged p21 construct. Transfected SUM159 cells were
then subjected to MTT assay (error bars indicate SD, n = 3).
Additional file 7: Figure S6: Effect of p21 depletion on serum and
EGF-stimulated cell migration. SCP2 cells were transfected with or
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without p21 siRNA. Cell invasion was assessed using the Transwell
Invasion assay. Total number of cells invaded was counted by Image J
(error bars indicate SEM; n = 3 independent experiments). * P < 0.05, n.s.,
non significant.
Additional file 8: Figure S7: Effect of TGFb on cofilin
phosphorylation and p21 nuclear localization. A, SCP2 and SUM159
cells were treated with or without 5 ng/ml TGFb for the indicated times.
Total cell lysates were analyzed for phospho-cofilin and colifin protein
levels by Western blotting. B, Immunocytochemistry was performed
using p21 (green) antibody and DAPI (blue). The scale bar is 10 µm.
Additional file 9: Figure S8: Effect of TGFb on acetylation of total
histone proteins. SCP2 cells were treated with TGFb and TSA for the
indicated times. Immunoblots of total histone proteins using an
acetylated lysine (Ac-Lysine) antibody.
Additional file 10: Figure S9: p21 is specifically overexpressed in
breast tumor cells. Representative immunohistochemistry images of
AE1/AE3 and p21 in lymph node negative (LN-) and positive (LN+) of
breast cancer tissue microarray samples.
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